cariprazine

Details

Files
Generic Name:
cariprazine
Project Status:
Active
Therapeutic Area:
Schizophrenia
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Vraylar
Project Line:
Reimbursement Review
Project Number:
SR0827-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
N/A delay outside our control - Deferral of recommendation by expert committee
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Resubmission
Fee Schedule:
Schedule A
Indications:
For the treatment of schizophrenia in adults.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open08-Nov-23
Call for patient/clinician input closed08-Jan-24
Clarification:

- Patient input submission received from Schizophrenia Society of Canada

Submission received20-Dec-23
Submission accepted11-Jan-24
Review initiated12-Jan-24
Draft CADTH review report(s) provided to sponsor for comment08-Apr-24
Deadline for sponsors comments17-Apr-24
CADTH review report(s) and responses to comments provided to sponsor09-May-24
Expert committee meeting (initial)22-May-24
Clarification:

Recommendation deferred to June 26, 2024 CDEC meeting

Draft recommendation issued to sponsor10-Jul-24
Draft recommendation posted for stakeholder feedback18-Jul-24
End of feedback period01-Aug-24
Final recommendation issued to sponsor and drug plans15-Aug-24
Final recommendation posted03-Sep-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)29-Aug-24
CADTH review report(s) posted-